<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268384</url>
  </required_header>
  <id_info>
    <org_study_id>APBCC_01</org_study_id>
    <nct_id>NCT01268384</nct_id>
  </id_info>
  <brief_title>Neoadjuvant FDR GX in Locally Advanced Pancreatic Cancer</brief_title>
  <official_title>Phase II Study of Fixed Dose Rate Gemcitabine Plus Capecitabine in Locally Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale for phase II trial of neoadjuvant fixed dose rate gemcitabine plus capecitabine&#xD;
      for patients with LAPC includes the following: First, obtaining a sufficient tumor&#xD;
      down-staging to procure R0/R1 resection, reported to be one of the most significant&#xD;
      prognostic factors for survival; second, providing an observation period to exclude from&#xD;
      surgery those patients with rapidly progressive disease there by to help select patients for&#xD;
      surgery who have the greatest likelihood of a favorable postoperative outcome; third,&#xD;
      eliminating micrometastatic disease, that is likely present in most patients, earlier than&#xD;
      adjuvant setting and preventing post-surgical growth spurts; fourth, adjuvant therapy given&#xD;
      in the neoadjuvant setting is better tolerated, as the patient has not recently undergone a&#xD;
      major operation; and the last, the lack of widely accepted optimal preoperative or palliative&#xD;
      approach in patients with LAPC, the majority of whom may not be operated on.&#xD;
&#xD;
      The primary goal is to determine the R0 resection rate of the neoadjuvant fixed dose rate&#xD;
      (FDR) gemcitabine-capecitabine combination chemotherapy in patients with borderline&#xD;
      resectable or unresectable locally advanced pancreatic adenocarcinoma.&#xD;
&#xD;
      The secondary goals are to assess progression-free survival (PFS) and OS (overall survival)&#xD;
      in these patients and to assess adverse events of these neoadjuvant treatments.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>6 months</time_frame>
    <description>Microscopic complete resection rate after neoadjuvant chemotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events associated with neoadjuvant chemotherapy</measure>
    <time_frame>6 months</time_frame>
    <description>NCI CTCAE v.3.0 based AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Overall survival after enrollment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>FDR_GX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose rate gemcitabine plus capecitabine every 3 weeks for 3-9 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine plus Capecitabine</intervention_name>
    <description>Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days</description>
    <arm_group_label>FDR_GX</arm_group_label>
    <other_name>Neoadjuvant chemotherapy</other_name>
    <other_name>GemCap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically documented pancreatic adenocarcinoma&#xD;
&#xD;
          -  Clinical T3 or T4 tumor according to AJCC staging system&#xD;
&#xD;
          -  Tumors considered as borderline resectable or unresectable disease assessed by&#xD;
             multidisciplinary team including pancreatic surgeon, gastroenterologist specializing&#xD;
             in pancreas, medical oncologist, and radiation oncologist&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  ECOG performance status 2 or less&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
               -  Adequate bone marrow function (WBCs&gt; 3,500/µL, absolute neutrophil count [ANC]&gt;&#xD;
                  1,500/µL, hemoglobin &gt; 9.0 g/dL, and platelets &gt; 100,000/µL)&#xD;
&#xD;
               -  Adequate kidney function (creatinine &lt; 1.5 mg/dL)&#xD;
&#xD;
               -  Adequate liver function (bilirubin &lt; 1.5 mg/dL [&lt;2.5 mg/dL for patients with&#xD;
                  obstructive jaundice due to pancreatic cancer with adequate decompression],&#xD;
                  transaminases levels &lt; 3 times the upper normal limit)&#xD;
&#xD;
          -  Patients must not have psychological, familial, sociological or geographical&#xD;
             conditions which do not permit medical follow-up and compliance with this study&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test on admission.&#xD;
             Post-menopausal women must have been amenorrheic for at least 12 months to be&#xD;
             considered of non-childbearing potential. Men and women of reproductive potential must&#xD;
             have agreed to use an effective method of contraception while on treatment and for 6&#xD;
             months after study treatment&#xD;
&#xD;
          -  The patient must be able to understand the study and has given written informed&#xD;
             consent to participate in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other tumor type than adenocarcinoma&#xD;
&#xD;
          -  Evidence of gastrointestinal bleeding or obstruction&#xD;
&#xD;
          -  Presence of the clinically relevant ascites or distant metastases&#xD;
&#xD;
          -  Past or concurrent history of malignant neoplasm, except for curatively treated&#xD;
             non-melanoma skin cancer or in situ carcinoma of the cervix uteri&#xD;
&#xD;
          -  Pregnant or lactating women, women of childbearing potential not employing adequate&#xD;
             contraception&#xD;
&#xD;
          -  Hypersensitivity to any of the study drugs or ingredients&#xD;
&#xD;
          -  Other serious illness or medical conditions&#xD;
&#xD;
               -  Unstable cardiac disease despite treatment, myocardial infarction within 6 months&#xD;
                  prior to study entry&#xD;
&#xD;
               -  History of significant neurologic or psychiatric disorders including dementia or&#xD;
                  seizures&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
               -  Pre-existing clinically significant diarrhea&#xD;
&#xD;
               -  Active peptic ulcer&#xD;
&#xD;
               -  Severe hypercalcemia of 12 mg/dL uncontrolled with bisphosphonates&#xD;
&#xD;
               -  Active disseminated intravascular coagulation&#xD;
&#xD;
               -  Other serious underlying medical conditions which could impair the ability of the&#xD;
                  patient to participate in the study&#xD;
&#xD;
          -  Concomitant or administration of any other experimental drug under investigation&#xD;
             within 3 weeks before the study&#xD;
&#xD;
          -  Concomitant chemotherapy, hormonal therapy, or immunotherapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Lyun Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>December 29, 2010</study_first_submitted>
  <study_first_submitted_qc>December 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2010</study_first_posted>
  <last_update_submitted>December 5, 2011</last_update_submitted>
  <last_update_submitted_qc>December 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>JLee</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

